Details of Drug-Drug Interaction
| Drug General Information (ID: DDIK2R1D45) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Zidovudine | Drug Info | Ribavirin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Anti-Hiv Agents | Antiviral Agents | |||||||
| Structure | |||||||||
| Mechanism of Zidovudine-Ribavirin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Zidovudine | Ribavirin | |||||||
| Mechanism | Prodrug activated by intracellular phosphorylation | Intracellular phosphorylation inhibitor | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Coadministration of ribavirin with zidovudine should generally be avoided. Patients should be advised to promptly seek medical attention if they experience symptoms of toxicity such as nausea, vomiting, abdominal pain/distention, fatigue, infection, unexplained weight loss, tachypnea, dyspnea, motor weakness, numbness, tingling, and pain in hands and feet. Dosage reduction or discontinuation of ribavirin should be considered if worsening toxicities are observed. | ||||||||